Finoriq research workspace
Royalty Pharma plc (RPRX) SEC Filings & Filing Highlights
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation. Review RPRX SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
- Company
- Royalty Pharma plc (RPRX)
- Ticker
- RPRX
- Market Cap
- $33.2B
- Latest Price
- $57.58
- Industry
- Biotech & Pharma
Royalty Pharma plc (RPRX) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Royalty Pharma plc (RPRX).
| Event | Form | Date |
|---|---|---|
| Proposal 1. To elect nine directors, each by separate ordinary resolutions, to the Company’s Bo...On June 4, 2026, Royalty Pharma plc (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “Annual Meeting”). At the Ann... | 8-K5.07 | 2026-06-04 |
| Royalty Pharma plc: Material agreementOn May 22, 2026, Royalty Pharma plc (the “Company”), Royalty Pharma Holdings Ltd, a non-wholly owned consolidated subsidiary of the Company... | 8-K1.01 | 2026-05-28 |
| Royalty Pharma plc: Earnings or resultsOn May 6, 2026, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of... | 8-K2.02 | 2026-05-06 |
| On April 13, 2026, Revolution Medicines, Inc. announced positive Phase 3 results from the RASol...On April 13, 2026, Revolution Medicines, Inc. (“Revolution Medicines”) announced positive Phase 3 results from the RASolute 302 trial for d... | 8-K7.01 | 2026-04-13 |
| Royalty Pharma plc: Earnings or resultsOn February 11, 2026, Royalty Pharma plc issued a press release announcing its financial results for the quarter and year ended December 31... | 8-K2.02 | 2026-02-11 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.